Characterize seroprevalence of sars COV-2 antibodies in the US population
Ended Definitive Contract Awarded Last action
- Contract number
- 75D30120C08170
- Awardee
-
Vitalant UEI GKT4L2JZJ622
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $46,421,050
Award facts
- Opportunity
-
- Modification to Contract 75D30120C08170 (National SARS-CoV-2 Seroincidence Studies in Blood Donors) Special Notice · 75D30120Q71772 · Posted Dec 16, 2021
- Contract value 100% obligated
- $46,421,050.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Cost No Fee
- Place of performance
- Scottsdale, AZ 85257, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$16,024 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $11,262,567 | |
| Change Order | $0 | |
| Funding Only Action | $2,516,554 | |
| Supplemental Agreement for work within scope | $11,221,162 | |
| Supplemental Agreement for work within scope | $16,921,661 | |
| Original award | $4,515,130 |
About this award
The Centers for Disease Control and Prevention Pittsburgh awarded a cost-reimbursable definitive contract to Vitalant Research Institute to characterize seroprevalence of SARS-CoV-2 antibodies in the US population on May 12, 2020, with a ceiling value of $46.4 million and an ultimate completion date of May 11, 2024.
The originating solicitation, issued as a special notice in December 2021, contemplated a sole-source modification under FAR 6.302-1, citing Vitalant's 18 months of prior experience on the longitudinal COVID-19 serosurvey work, established blood collection partnerships, and data management capabilities as the only source capable of immediate performance. The contract expanded longitudinal participation to approximately 130,000 blood donors and supported the National SARS-CoV-2 Seroincidence Studies in Blood Donors, providing data on antibody stability, reinfection risk, and serosurvey analysis accounting for waning immune responses across geographic and demographic segments.
Place of performance is Scottsdale, AZ. Creative Testing Solutions subcontracted quantitative immunoglobulin and nucleocapsid testing on sample batches at specified per-test rates, with a March 2024 amendment increasing the subcontract award by $200,000 to $769,088 to cover additional work through the project end date.
Government-invoiced labor peaked in FY2023 at $12.9 million across 15.3 FTEs and 31,853 contractor hours ($403.99 blended hourly rate), declining in FY2024 to $3.5 million across 7.3 FTEs and 15,266 hours ($231.92/hr), with 48 percent of contractor hours subcontracted in the most recent year.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Creative Testing Solutions | $200,000 |
Quick answers
Who was awarded contract 75D30120C08170?
75D30120C08170 was awarded to Vitalant by CDC Pittsburgh (Centers for Disease Control and Prevention) on May 12, 2020.
How much is contract 75D30120C08170 worth?
The government has obligated $46,421,050 on 75D30120C08170.
Was contract 75D30120C08170 competed?
The extent of competition for 75D30120C08170 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award